Kroger Co vs 10X Genomics Inc — how do they compare? Kroger Co trades at $61.64 (market cap $36.27B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: Kroger Co is far larger — about 3.6× 10X Genomics Inc's market cap, and Kroger Co pays a 2.54% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 108 Days and 10X Genomics Inc for 91 Days on average.
| KR | TXG | |
|---|---|---|
Market Cap | $36.27B | $10.07B |
Volume | 8,301,523 | 5,657,286 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $97.74 |
52-Week Low | $55.53 | $11.48 |
Typical Hold Time | 108 Days | 91 Days |
Enterprise Value | $57.69B | $9.59B |
Dividend Yield | 2.54% | — |
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $61.41, up 3.65% with a bullish technical outlook. The stock shows strong fundamentals with $147.12B revenue and $2.67B net income for 2025, though net margin remains thin at 0.73%. Recent earnings beat expectations in Q2 2026, and the company maintains consistent dividends. Analysts are moderately bullish with a $70.62 consensus target, citing digital growth and operational improvements as key drivers.
KR offers value with low P/S (0.26) and stable cash flow generation, but faces risks from competitive pressures and integration challenges from acquisitions. The stock presents opportunity for investors seeking defensive exposure with dividend income, though margin compression and economic sensitivity warrant caution.
TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.
The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →